Leukemia: Chronic Lymphocytic Leukemia (CLL)

    Actionable Target Abnormality Clinical Experience with Targeted Agent
    CD20 Present Fludarabine + cyclophosphamide + rituximab (anti-CD20 antibody) (FCR): • Phase 3: RR 90% (CR 44%), PFS 51.8 mo, OS 87% at 3 yr (33)
    Ofatumumab (anti-CD20 antibody):
    • Phase 2 (34)
    • Rituxan-treated: RR 43%, mPFS 5.3 mo, mOS 15.5 mo
    • Rituxan-refractory: RR 44%, mPFS 5.5 mo, mOS 15.5 moRituxan-naïve: RR 53%, mPFS 5.6 mo, mOS 20.2 mo
    Obinutuzumab (anti-CD20 antibody):
    • Phase 3, with chlorambucil: PFS 26.7 mo, RR 77.3% (CR 22.3%, PR 55%) at 3 mo, hazard ratio 0.41 (95% CI 0.23–0.74) compared with chlorambucil monotherapy (35)
    Other topics in Targets by Organ Site